White House Industrial Strategy Raises Specter of Generic Drug Tariffs — Panjiva


White House Industrial Strategy Raises Specter of Generic Drug Tariffs

China 1758 Health Care 108 India 283 Singapore 46 Tariffs 1169 U.S. 3297

The White House’s new advanced manufacturing strategy includes the need to “assure access to medical products” and identifies foreign dominance in small molecule, generic pharmaceuticals as a national security risk. It’s not a stretch to see that leading to a section 232 national security review of imports, in line with prior reviews of the steel, aluminum and autos sectors. America’s soaring demand for healthcare services drove $128.6 billion of pharmaceutical and precursor imports in the 12 months to Sept. 30, up 16.8% on a year earlier. Asian markets only...

PANJIVA RESEARCH is a service provided by Panjiva, Inc. ("Panjiva") to relevant global subscribers, and are deemed to be Panjiva "Services" subject to the Panjiva Terms & Conditions of Use. Information contained within or made available via the Services is for informational purposes only and nothing in the Services shall constitute or be construed as an offering of financial instruments, or as investment advice or recommendations by Panjiva, Inc. or its affiliates of an investment strategy or whether to "buy", "sell" or "hold" an investment. The Services may include views and commentary about customers of Panjiva. No aspect of the Services is based on consideration of your individual circumstances, and you should determine on your own whether you agree with the information contained within or made available via the Services. Employees involved in Panjiva Research may hold positions in securities analyzed or discussed in the Services. Panjiva does not make any express or implied warranties, representations, endorsements or conditions with respect to the Services and the information contained within or made available via the Services, including without limitation, warranties as to the usefulness, completeness, accuracy, currentness, reliability or sufficiency of any information (including, without limitation, conclusions, statements, opinions, estimates, forecasts or projections of any kind) and expressly disclaims any implied warranties. Neither this disclaimer nor any of its contents may be forwarded or redistributed without the prior written consent of Panjiva. © 2019 Panjiva, Inc. All Rights Reserved.